{"id":"nasvac","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NASVAC combines recombinant hepatitis B surface antigen with immunomodulatory components to enhance T-cell and B-cell mediated immunity in chronically infected patients. The vaccine aims to restore immune control of HBV replication and potentially achieve functional cure (HBsAg loss) in combination with antiviral therapy or as monotherapy.","oneSentence":"NASVAC is a therapeutic vaccine designed to stimulate immune responses against hepatitis B surface antigen (HBsAg) in chronic hepatitis B patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:48.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT01374308","phase":"PHASE3","title":"NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients","status":"UNKNOWN","sponsor":"Clinical Research Organization, Dhaka, Bangladesh","startDate":"2011-06","conditions":"Chronic Hepatitis B","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NASVAC","genericName":"NASVAC","companyName":"Clinical Research Organization, Dhaka, Bangladesh","companyId":"clinical-research-organization-dhaka-bangladesh","modality":"Biologic","firstApprovalDate":"","aiSummary":"NASVAC is a therapeutic vaccine designed to stimulate immune responses against hepatitis B surface antigen (HBsAg) in chronic hepatitis B patients. Used for Chronic hepatitis B infection (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}